Temporal trends in Plasmodium vivax diversity in eastern Cambodia evidence declining transmission

Genotyping of *Plasmodium vivax* isolates in eastern Cambodia from 2014 to 2023 reveals a significant decline in parasite diversity and an increase in inbreeding, providing genetic evidence that widespread radical cure interventions have successfully reduced malaria transmission.

The Gist

Imagine malaria as a sneaky, invisible ghost that haunts a village. Most people know the ghost shows up when you get sick, but with Plasmodium vivax (a specific type of malaria), the ghost has a secret hiding spot: your liver. Even after you feel better, the ghost can sleep there for months or years, wake up, and start the infection all over again. This makes getting rid of the disease incredibly hard.

In eastern Cambodia, the government has been fighting this ghost for years. They introduced a special medicine (Primaquine) designed to burn down the ghost's hiding spot in the liver. But how do you know if the medicine is actually working? You can't just count the sick people, because sometimes the numbers go up and down for other reasons.

This paper is like a "genetic detective story." Instead of just counting sick people, the scientists looked at the "DNA fingerprints" of the malaria parasites found in patients. Here is what they discovered, explained simply:

1. The "Party" Analogy (Polyclonal Infections)

Think of a malaria infection like a party in a house.

• High Transmission (The Wild Party): In the past (2014, 2015, 2019), mosquitoes were biting people so often that a single person's house would get invaded by many different groups of parasites at once. It was a chaotic, crowded party with many different "guests" (genetic clones) mixing together. This is called a polyclonal infection.
• The Result: In 2019, there was a huge spike in these "wild parties" (48% of patients had them). This happened because malaria control services were temporarily paused, allowing the mosquitoes to run wild again.
• Low Transmission (The Quiet House): By 2023, after the new medicine was rolled out, the "parties" almost disappeared. Only 5% of patients had multiple guests. Most houses had just one lonely parasite, or none at all. This tells us the mosquitoes are biting far less often.

2. The "Family Tree" Analogy (Relatedness)

The scientists also looked at how closely related the parasites were to each other.

• The Bottleneck: Imagine a crowded room where everyone is different. If you suddenly lock the door and only let a few specific people stay, those few people will eventually become the ancestors of everyone else in the room. They will all look very similar because they are closely related.
• What Happened in 2023: The data showed that in 2023, the parasites were extremely similar to each other (81% were nearly identical). This is a sign of a "bottleneck." The population crashed so hard that only a few strains survived, and they are now inbreeding. It's like a family reunion where everyone is a second cousin because the family got so small.

3. The "Spiky" Timeline

The story of the data looks like a rollercoaster:

• 2014-2015: Steady, moderate chaos.
• 2019: A massive spike in chaos (high diversity, many different strains) because control efforts were interrupted.
• 2023: A sudden drop into silence. The genetic diversity plummeted, and the parasites became clones of each other.

Why Does This Matter?

The scientists found that the genetic data matched the number of sick people perfectly.

• When the number of sick people went up, the genetic "chaos" went up.
• When the number of sick people went down, the genetic "chaos" vanished, and the parasites became a small, related family.

The Big Takeaway:
The new strategy of giving patients a medicine that kills the liver "ghosts" (Primaquine) is working. The genetic fingerprints prove that the malaria parasite population in eastern Cambodia has shrunk dramatically and is losing its diversity. It's no longer a wild, chaotic invasion; it's a dying, isolated group of parasites.

This study proves that by looking at the "DNA fingerprints" of the parasite, we can tell if our malaria-fighting strategies are working long before we see the final numbers on a chart. It's like checking the smoke in the kitchen to know if the fire is out, rather than waiting to see if the house is cold.

Technical Summary

1. Problem Statement

Eliminating Plasmodium vivax malaria is particularly difficult due to the parasite's ability to form dormant liver stages (hypnozoites) that cause relapses weeks or months after the initial infection. In high-transmission settings, relapses account for up to 85% of recurrences. While clinical case numbers in Cambodia have declined over the last decade, traditional surveillance methods struggle to monitor the hidden reservoirs of infection (liver, spleen, and asymptomatic blood stages) and assess the true efficacy of interventions.

The study addresses the need for a more sensitive molecular tool to:

• Correlate genetic diversity with transmission intensity.
• Assess the impact of radical cure interventions (specifically primaquine) on the parasite population.
• Distinguish between superinfection (new bites) and relapse-driven transmission.

2. Methodology

Study Design and Sampling:

• Location: Eastern Cambodia (Rattanakiri and Mondulkiri provinces).
• Timeframe: Samples collected in four distinct years: 2014, 2015, 2019, and 2023.
• Cohort: 182 symptomatic P. vivax patients (confirmed via RDT and species-specific PCR).
• Context: The timeline captures a period of intervention fluctuation, including a spike in cases in 2019 due to the suspension of malaria control services, followed by the nationwide rollout of radical cure (primaquine) starting in 2019 and fully implemented in 2021.

Genotyping and Sequencing:

• Panel: The vivaxGEN microhaplotype panel, comprising 93 highly informative microhaplotype markers (originally 98, one failed).
• Workflow:
  • Library preparation using rhAmpSeq (multiplex PCR followed by indexing).
  • Sequencing on Illumina MiniSeq (150 bp paired-end reads).
  • Bioinformatics: Data processed via the vivaxGEN-MicroHaps pipeline (using cutadapt for trimming, DADA2 for denoising/ASV generation).
  • Filtering: Haplotypes with <2% occurrence or <5 read pairs were filtered; samples required >75% genotype calls.

Population Genetic Analysis:

• Within-Host Diversity:
  • Polyclonality: Probability of multiple clones per infection (threshold >50%).
  • Effective Multiplicity of Infection (eMOI): Calculated using MOIRE software.
• Between-Host Relatedness:
  • Identity-by-Descent (IBD): Calculated using Dcifer to measure recent ancestry. Infections were categorized as low-moderate (IBD 0–0.25), high (0.25–0.95), or identical/near-identical (>0.95).
  • Identity-by-State (IBS): Used for neighbor-joining trees and Principal Coordinate Analysis (PCoA).
• Population Diversity:
  • Expected Heterozygosity: Calculated to measure population-level genetic variation.
  • Differentiation: $F_{ST}$ and standardized $G''_{ST}$ calculated between the two provinces.

3. Key Contributions

• First Temporal IBD Analysis for P. vivax: This is the first study to utilize a high-resolution microhaplotype panel (93 markers) to track temporal trends in P. vivax relatedness (IBD) over a decade, moving beyond low-resolution microsatellites.
• Validation of Genetic Surveillance: Demonstrates that genetic metrics derived from symptomatic cases can serve as a robust proxy for transmission intensity and intervention efficacy, correlating strongly with clinical case counts.
• Evidence of Bottlenecking: Provides genetic evidence of a population bottleneck and inbreeding in P. vivax following the implementation of radical cure strategies.

4. Key Results

Correlation with Clinical Data:

• Genetic diversity trends mirrored the clinical case counts: a spike in 2019 followed by a sharp decline in 2023.

Within-Host Diversity (Transmission Intensity):

• Polyclonality: Decreased significantly from 22–48% in earlier years (2014, 2015, 2019) to 5% in 2023 ($p < 0.05$). This indicates a massive reduction in superinfection and co-transmission.
• eMOI: Showed a significant increase between 2015 and 2019 (coinciding with the 2019 case spike) followed by a sharp reduction in 2023 ($p = 2.507 \times 10^{-6}$).
• 2019 Anomaly: A spike in polyclonality (48%) and diversity in 2019 was linked to the temporary suspension of malaria control services (Global Fund suspension), leading to increased transmission.

Between-Host Relatedness (Population Structure):

• IBD Trends: A dramatic shift was observed in 2023. 81.4% of 2023 infections had an IBD >0.95 with at least one other infection in the same year, compared to only 8.9–10.8% in 2014–2019.
• Interpretation: This high level of identity indicates inbreeding and a severe population bottleneck, suggesting the parasite population is shrinking and becoming dominated by a few closely related lineages.
• Geographic Homogeneity: Low $F_{ST}$ values (0.018–0.028) between Rattanakiri and Mondulkiri confirmed that the two provinces share a highly connected parasite population, justifying pooled analysis.

Population Diversity:

• Mean expected heterozygosity dropped significantly in 2023 (range 0.009 to 0.074), confirming a loss of genetic diversity consistent with reduced transmission.

5. Significance and Implications

• Proof of Concept for Elimination: The study validates that microhaplotype genotyping is a powerful tool for monitoring P. vivax elimination progress. The genetic data confirmed that the widespread use of primaquine radical cure (rolled out 2021) successfully reduced the parasite reservoir.
• Intervention Efficacy: The sharp decline in polyclonality and the rise in identical strains (IBD >0.95) provide molecular evidence that the intervention is breaking the cycle of transmission and reducing the diversity of the circulating parasite population.
• Surveillance Strategy: The findings support the use of genetic surveillance on symptomatic cases as a complementary metric to routine case reporting, especially in low-transmission settings where detecting hidden reservoirs is difficult.
• Future Directions: The authors note limitations regarding the lack of data on asymptomatic reservoirs and patient demographics. Future studies should investigate how these factors influence diversity in low-endemic settings to refine sampling strategies for elimination programs.